Correction to: Clin Transl Oncol https://doi.org/10.1007/s12094-017-1800-5

On page 5 of the article, in the last paragraph of the section “Prognostic genetic platforms: molecular phenotypes and translation to the clinic” a relevant discrepancy between the text and Table 1 could be misunderstood, therefore the paragraph was corrected. The corrected version as well as some changes in Tables 1 and 2 that reflect the updated modifications are shown here:

Table 1 Usage recommendations for different genetic tests as prognostic tools or to establish the benefit of adding chemotherapy to hormone therapy in the management of breast cancer
Full size table
Table 2 Prognostic and predictive value of different genetic tests in breast cancer
Full size table

The 2017 update of the ASCO Clinical Practice Guideline of Biomarkers use for the adjuvant therapy of breast cancer, focused on the use of MammaPrint®, specified that MammaPrint® may be used in patients with HR+, HER2-negative cases with high clinical risk per MINDACT, either without lymph node involvement or with 1–3 positive nodes, to inform decisions on withholding adjuvant chemotherapy. However, the ASCO guideline warns that these patients should be informed that a benefit of chemotherapy cannot be excluded, particularly in patients with > 1 nodes involved. On the other hand, MammaPrint® does not have a use in either the ER/PR positive low-risk category, in patients with HER2 + or triple-negative breast cancer, according to the guideline [54].